معرفی
Dr. David Sumpton serves as an Honorary Senior Lecturer within the School of Cancer Sciences at the University of Glasgow, affiliated with the CRUK Scotland Institute in Glasgow. His research bridges cancer biology, metabolism, and therapeutic development, with particular focus on mitochondrial function in malignancies.
His research interests center on cancer metabolism, especially mitochondrial pathways driving tumor progression and metastasis. Key areas include nucleotide metabolism (uridine phosphorylase), folate cycle regulation in leukemia, lipid signaling in metastatic niches, and immunometabolism interactions. His work demonstrates how metabolic rewiring enables immune evasion, metastatic colonization, and therapeutic resistance across prostate cancer, leukemia, and solid tumors.
Analysis of his 2023-2025 publications reveals strong emphasis on metabolic vulnerabilities for therapeutic targeting, including drug repurposing (lomerizine for CML), mitochondrial DNA mutations enhancing immunotherapy response, and nutrient transporter dependencies (SLC7A5). His team frequently employs multi-omics approaches to stratify cancer subtypes and identify biomarker-driven treatments.
While no formal advising or grant information is publicly documented, his collaborative publications across Nature journals, Science Translational Medicine, and Cell Biology indicate extensive institutional partnerships. His lab appears focused on translating metabolic discoveries into preclinical therapeutic strategies, particularly for treatment-resistant cancers.
Dr. Sumpton maintains active research in tumor microenvironment dynamics, with recent work on extracellular vesicle-mediated metastatic niche formation and senescence-induced multi-organ dysfunction. His team utilizes physiological cell culture models to improve metabolic fidelity in cancer research.
